Literature DB >> 26114180

Non-invasive distinction of non-alcoholic fatty liver disease using urinary volatile organic compound analysis: early results.

Ramesh P Arasaradnam1, Michael McFarlane2, Emma Daulton3, Erik Westenbrink3, Nicola O'Connell2, Subiatu Wurie2, Chuka U Nwokolo2, Karna D Bardhan4, Richard S Savage5, James A Covington3.   

Abstract

BACKGROUND & AIMS: Non-Alcoholic Fatty Liver Disease (NAFLD) is the commonest cause of chronic liver disease in the western world. Current diagnostic methods including Fibroscan have limitations, thus there is a need for more robust non-invasive screening methods. The gut microbiome is altered in several gastrointestinal and hepatic disorders resulting in altered, unique gut fermentation patterns, detectable by analysis of volatile organic compounds (VOCs) in urine, breath and faeces. We performed a proof of principle pilot study to determine if progressive fatty liver disease produced an altered urinary VOC pattern; specifically NAFLD and Non-Alcoholic Steatohepatitis (NASH).
METHODS: 34 patients were recruited: 8 NASH cirrhotics (NASH-C); 7 non-cirrhotic NASH; 4 NAFLD and 15 controls. Urine was collected and stored frozen. For assay, the samples were defrosted and aliquoted into vials, which were heated to 40±0.1°C and the headspace analyzed by FAIMS (Field Asymmetric Ion Mobility Spectroscopy). A previously used data processing pipeline employing a Random Forrest classification algorithm and using a 10 fold cross validation method was applied.
RESULTS: Urinary VOC results demonstrated sensitivity of 0.58 (0.33 - 0.88), but specificity of 0.93 (0.68 - 1.00) and an Area Under Curve (AUC) 0.73 (0.55 - 0.90) to distinguish between liver disease and controls. However, NASH/NASH-C was separated from the NAFLD/controls with a sensitivity of 0.73 (0.45 - 0.92), specificity of 0.79 (0.54 - 0.94) and AUC of 0.79 (0.64 - 0.95), respectively.
CONCLUSIONS: This pilot study suggests that urinary VOCs detection may offer the potential for early non-invasive characterisation of liver disease using 'smell prints' to distinguish between NASH and NAFLD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26114180     DOI: 10.15403/jgld.2014.1121.242.ury

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  5 in total

1.  Urinary Volatile Organic Compounds as Potential Biomarkers in Idiopathic Membranous Nephropathy.

Authors:  Mingao Wang; Rujuan Xie; Xibei Jia; Ruichan Liu
Journal:  Med Princ Pract       Date:  2017-06-19       Impact factor: 1.927

Review 2.  Interaction of volatile organic compounds and underlying liver disease: a new paradigm for risk.

Authors:  Anna L Lang; Juliane I Beier
Journal:  Biol Chem       Date:  2018-10-25       Impact factor: 4.700

3.  Urinary volatile organic compounds in overweight compared to normal-weight children: results from the Italian I.Family cohort.

Authors:  Rosaria Cozzolino; Beatrice De Giulio; Pasquale Marena; Antonella Martignetti; Kathrin Günther; Fabio Lauria; Paola Russo; Matteo Stocchero; Alfonso Siani
Journal:  Sci Rep       Date:  2017-11-15       Impact factor: 4.379

4.  Pre-analytical and analytical variables that influence urinary volatile organic compound measurements.

Authors:  Michael McFarlanE; Ella MozdiaK; Emma Daulton; Ramesh Arasaradnam; James Covington; Chuka Nwokolo
Journal:  PLoS One       Date:  2020-07-31       Impact factor: 3.240

5.  Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome.

Authors:  Ahmad Moolla; Jasper de Boer; David Pavlov; Amin Amin; Angela Taylor; Lorna Gilligan; Beverly Hughes; John Ryan; Eleanor Barnes; Zaki Hassan-Smith; Jane Grove; Guruprasad P Aithal; An Verrijken; Sven Francque; Luc Van Gaal; Matthew J Armstrong; Phillip N Newsome; Jeremy F Cobbold; Wiebke Arlt; Michael Biehl; Jeremy W Tomlinson
Journal:  Aliment Pharmacol Ther       Date:  2020-04-16       Impact factor: 9.524

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.